Produit
AGENTS IA
APPLICATIONS DE L'IA
AUTRES
Solutions
SECTEURS D'ACTIVITÉ
Tarification
Ressources
EXPLORER
ENGAGER
ASSISTANCE ET SERVICES
À propos
Plateforme PatSnap Eureka
Mandataires en propriété intellectuelle
Agents pour l'ingénierie
Agents pour les sciences de la vie
Agents pour matériaux
Analytique
Intelligence IPSynapse
Renseignement biopharmaceutiqueBiographie
Recherche et analyse de séquences biologiquesChimique
Recherche et analyse de structures chimiquesPlateforme ouverte
Services professionnels
Témoignages clients
Newsroom
Blog
Rapport mondial sur l'innovation
Glossaire
Webinaires et formations
Frontière
Communauté d'utilisateurs
Confiance et sécurité
PatentBench
LLM
Centre d'aide
Carrières
Accès à plus de 2 000 000 000 points de données structurées dans les domaines des brevets, des sciences, des litiges et des technologies.
Innovez 75 % plus vite à un coût réduit de 25 %.
Cloud ou sur site pour une confidentialité et un contrôle maximaux
Reconnu par plus de 18 000 innovateurs à travers le monde
Pour l'utiliser, cliquez sur le bouton de vérification dans l'e-mail que nous avons envoyé à [email protected].
Cela contribue à sécuriser votre compte.
Vous devriez le recevoir sous peu. N'oubliez pas de vérifier votre dossier spam.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Série soigneusement sélectionnée offrant des informations précieuses aux professionnels de l'innovation.
Article | Rapport Explore the core engineering challenges in next-generation flow chemistry platforms for continuous pharmaceutical synthesis, from reactor fouling to regulatory compliance.
Article | Rapport Patent and literature evidence maps ethanol's role as a marine fuel in 2026: combustion approaches, key assignees, geographic hotspots, and emerging IP white spaces.
Article | Rapport HIL vs SIL testing for autonomous vehicle validation: understand the key differences, use cases, and how each method fits the V-model development cycle.
Article | Rapport Sanofi's rilzabrutinib is a reversible BTK inhibitor in Phase III trials for immune thrombocytopenia. Explore late-stage data and the competitive landscape.
Article | Rapport The zinc-ion battery materials landscape for grid-scale energy storage in 2026: key research directions, patent intelligence gaps, and how to navigate this emerging space.
Article | Rapport Explore the key engineering tradeoffs between direct and indirect hydrogen storage for mobile fuel cell applications, from compressed gas to LOHC and ammonia cracking.
Article | Rapport Mapping the 2026 continuous lactate monitor landscape: patent leaders, sensor technologies, clinical applications, and emerging IP white spaces across ICU, sports, and beyond.
Article | Rapport Amlitelimab's Phase III SOLO program targets drug-free remission in atopic dermatitis — a paradigm shift beyond dupilumab. Explore the OX40L mechanism and competitive landscape.
Article | Rapport Mapping the 2026 on-orbit satellite servicing patent landscape: engagement systems, debris removal, logistics optimisation, and emerging IP white spaces.
Article | Rapport SIL vs Performance Level: compare IEC 62061 and ISO 13849 certification frameworks for industrial machine guarding systems. Key differences explained.
Article | Rapport Tolebrutinib's EMA conditional approval and FDA resubmission in non-relapsing SPMS marks a landmark for CNS-targeted BTK inhibition. What it means for progressive MS.
Article | Rapport How PIM architecture is dismantling the memory wall: technology clusters, application domains, geographic leaders, and 2026 strategic IP opportunities across 70+ records.
Article | Rapport Wind turbine blade recyclability is one of renewable energy's most urgent engineering challenges. Explore the key technical barriers, material science gaps, and innovation pathways driving circular blade design.
Article | Rapport Zola-cel (BMS CD19 CAR-T) in the BREAKFREE trial: autoimmune disease data, mechanism, and competitive landscape vs. KYV-101 by Kyverna Therapeutics.
Article | Rapport How to build a rigorous SAC patent and literature landscape for hydrogen evolution and CO₂ reduction — data requirements, IPC codes, and search strategy.